Changes in Beneficial Ownership · 4
Lyell Immunopharma, Inc.
LYELNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08252026_080833.xml
Filing details
- Report period
- 2026-08-21
- Issuer
- Lyell Immunopharma, Inc.
- Issuer CIK
- 0001806952
- Trading symbol
- LYEL
Reporting owner 1
- Name
- Seely Lynn
- Reporting owner CIK
- 0001327111
- Relationship
- Director · Officer
- Officer title
- President and CEO
- Address
- C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-21 | S · Form 4 | 9,589[F1] | D | 15.54 | 63,899 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Mark Meltz, Attorney-in-Fact
- Date
- 2026-08-25
Company context
Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s lead product candidate, LYL314, is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19-targeted CAR T-cell therapies for the treatment of large B-cell lymphoma. The PiNACLE trial is an ongoing single-arm pivotal trial evaluating LYL314 in patients with large B-cell lymphoma that has relapsed and/or been refractory to two or more lines of prior therapy. The Lyell LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com.